Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

Reuters2026/08/13 12:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Atrium Therapeutics earned a USD 15 million milestone payment from Bristol Myers Squibb tied to delivery of a lead cardiovascular compound.
Payment falls under a global licensing and research collaboration covering multiple RNA-based cardiovascular programs.
Agreement includes eligibility for up to about USD 1.35 billion in R&D milestones, up to about USD 825 million in commercial milestones.
Bristol Myers Squibb will fund future clinical development, regulatory filings, and commercialization for programs from the collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration

You may also like

Crypto prices